BR112020006658A2 - métodos de tratamento de infecções bacterianas - Google Patents

métodos de tratamento de infecções bacterianas Download PDF

Info

Publication number
BR112020006658A2
BR112020006658A2 BR112020006658-3A BR112020006658A BR112020006658A2 BR 112020006658 A2 BR112020006658 A2 BR 112020006658A2 BR 112020006658 A BR112020006658 A BR 112020006658A BR 112020006658 A2 BR112020006658 A2 BR 112020006658A2
Authority
BR
Brazil
Prior art keywords
individual
vaborbactam
meropenem
fact
administered
Prior art date
Application number
BR112020006658-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Elizabeth Alexander
Jeff Loutit
Michael N. Dudley
Original Assignee
Melinta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020006658(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics, Inc. filed Critical Melinta Therapeutics, Inc.
Publication of BR112020006658A2 publication Critical patent/BR112020006658A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112020006658-3A 2017-10-03 2018-10-01 métodos de tratamento de infecções bacterianas BR112020006658A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US62/567,702 2017-10-03
US201862657402P 2018-04-13 2018-04-13
US62/657,402 2018-04-13
PCT/US2018/053772 WO2019070591A1 (en) 2017-10-03 2018-10-01 METHODS OF TREATING BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
BR112020006658A2 true BR112020006658A2 (pt) 2020-09-24

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020006658-3A BR112020006658A2 (pt) 2017-10-03 2018-10-01 métodos de tratamento de infecções bacterianas

Country Status (16)

Country Link
US (3) US11376237B2 (cg-RX-API-DMAC7.html)
EP (1) EP3691652A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020536092A (cg-RX-API-DMAC7.html)
KR (1) KR20200066664A (cg-RX-API-DMAC7.html)
CN (1) CN111432821A (cg-RX-API-DMAC7.html)
AU (1) AU2018345317B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006658A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078238A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000892A1 (cg-RX-API-DMAC7.html)
JO (1) JOP20200075A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003670A (cg-RX-API-DMAC7.html)
MY (1) MY200934A (cg-RX-API-DMAC7.html)
PH (1) PH12020550249A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003009QA (cg-RX-API-DMAC7.html)
TW (2) TW202400146A (cg-RX-API-DMAC7.html)
WO (1) WO2019070591A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018345317B2 (en) * 2017-10-03 2024-10-24 Melinta Therapeutics, Inc. Methods of treating bacterial infections
EP4313033A4 (en) * 2021-03-24 2025-04-23 Trustees Of Tufts College BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
RU2675847C2 (ru) 2013-05-28 2018-12-25 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
WO2016172208A1 (en) * 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
EP3319609B1 (en) 2015-07-09 2022-06-15 Washington University Compositions and methods of use of antibacterial drug combinations
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
US12478606B2 (en) 2017-01-09 2025-11-25 Melinta Subsidiary Corp. Methods of treating bacterial infections
AU2018345317B2 (en) 2017-10-03 2024-10-24 Melinta Therapeutics, Inc. Methods of treating bacterial infections

Also Published As

Publication number Publication date
SG11202003009QA (en) 2020-04-29
EP3691652A1 (en) 2020-08-12
TW201922241A (zh) 2019-06-16
US20260102374A1 (en) 2026-04-16
AU2018345317B2 (en) 2024-10-24
MY200934A (en) 2024-01-24
US20200297695A1 (en) 2020-09-24
US20220288024A1 (en) 2022-09-15
CA3078238A1 (en) 2019-04-11
MX2020003670A (es) 2020-08-03
US11376237B2 (en) 2022-07-05
JP2020536092A (ja) 2020-12-10
KR20200066664A (ko) 2020-06-10
WO2019070591A1 (en) 2019-04-11
JOP20200075A1 (ar) 2020-04-30
EP3691652A4 (en) 2021-07-07
CN111432821A (zh) 2020-07-17
TW202400146A (zh) 2024-01-01
AU2018345317A1 (en) 2020-05-07
PH12020550249A1 (en) 2021-02-15
CL2020000892A1 (es) 2020-10-23
US12533342B2 (en) 2026-01-27

Similar Documents

Publication Publication Date Title
Willems et al. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics
EP3505161B1 (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
US20090226393A1 (en) Polymer paclitaxel conjugates and methods for treating cancer
US20260102374A1 (en) Methods of treating bacterial infections
JP2015163635A (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
JP2025087858A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
WO2022104022A1 (en) Rapidly infusing compositions with methotrexate and treatment methods
TWI468161B (zh) 組合藥劑之醫藥產品、試劑及用途
US12502363B2 (en) Ketamine and ketamine/nap for treatment of ADNP syndrome and related neurological conditions
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
WO2024120523A1 (zh) 一种治疗前列腺癌的药物组合及其应用
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
WO2025064688A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
CN119367338A (zh) 天然产物苏木查尔酮作为成纤维细胞激活蛋白抑制剂的应用
BR112021003686B1 (pt) Composição farmacêutica na forma de comprimido oral compreendendo inibidores de pde9
HK40009745A (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
HK40009745B (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo
WO2008055386A1 (fr) Composition pharmaceutique hydrosoluble pour injection de 17-allyl amino-17-déméthoxy geldanamycine (17-aag)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]